Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Drug targets
All targetsApprovals worldwideDrug spending
Protein target · ChEMBL and the Guide to Pharmacology

Medicines acting on NTRK3

Neurotrophic receptor tyrosine kinase 3. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.

Sources: ChEMBL (CC BY-SA 3.0) via the Open Targets Platform, release 26.09; IUPHAR/BPS Guide to PHARMACOLOGY 2026.3 (CC BY-SA 4.0). ENSG00000140538
5Medicines acting on NTRK3 (5 with a page here)
2 of 5Listed by both ChEMBL and the Guide to Pharmacology
41Current clinical trials of these medicines in our registers
InhibitorMost common way they act (4 of 5)
01

Medicines acting on NTRK3

most-trialled first
MedicineHow it actsSourceCurrent trials here
Entrectinib
CHEMBL1983268
Neurotrophic tyrosine kinase receptor inhibitor Inhibitor
Small molecule
 ChEMBL only 15
Larotrectinib
CHEMBL3889654
Neurotrophic tyrosine kinase receptor inhibitor Inhibitor
Small molecule
 ChEMBL only 11
Repotrectinib
CHEMBL4298138
NT-3 growth factor receptor inhibitor Inhibitor
Small molecule
 ✓ Both 7
Taletrectinib
CHEMBL4650989
Neurotrophic tyrosine kinase receptor inhibitor Inhibitor
Small molecule
 ✓ Both 6
Cenegermin
CHEMBL4297852
Neurotrophic tyrosine kinase receptor agonist Agonist
Protein
 ChEMBL only 2

“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.

02

Diseases these medicines are tested for

by number of NTRK3 medicines
DiseaseMedicines testedFurthest trial phase
Non-small cell lung carcinoma 2 Phase 3
Breast cancer 2 Phase 2
Colorectal cancer 2 Phase 2
Invasive lobular breast carcinoma 2 Phase 2
Medullary thyroid gland carcinoma 2 Phase 2
Plasma cell myeloma 2 Phase 2
Poorly differentiated thyroid gland carcinoma 2 Phase 2
Childhood malignant neoplasm 1 Phase 2/3
Acute leukemia 1 Phase 2
Adenocarcinoma 1 Phase 2
Central nervous system cancer 1 Phase 2
Central nervous system neoplasm 1 Phase 2
Congenital fibrosarcoma 1 Phase 2
Differentiated thyroid carcinoma 1 Phase 2
Digestive system neoplasm 1 Phase 2

From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).

A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.